Twist Bioscience (TWST) Equity Average (2018 - 2026)

Twist Bioscience (TWST) has 9 years of Equity Average data on file, last reported at $455.6 million in Q1 2026.

• Equity Average for Q1 2026 came in at $455.6 million, up 1.69% year-over-year; the trailing twelve-month figure through Mar 2026 was $455.6 million (up 1.69% YoY), and the FY2025 annual result was $472.8 million, down 13.73% from the prior year.
• Equity Average slipped to $455.6 million in Q1 2026 per TWST's latest filing, from $464.5 million in the prior quarter.
• Over five years, Equity Average peaked at $842.0 million in Q2 2022 and troughed at $448.0 million in Q1 2025.
• A 5-year average of $597.8 million and a median of $575.1 million in 2024 frame the typical range for Equity Average.
• The sharpest annual moves came in 2022 and 2024: Equity Average surged 37.51% in 2022, then dropped 24.76% in 2024.
• A 5-year view of Equity Average shows it stood at $767.9 million in 2022, then slipped by 20.98% to $606.7 million in 2023, then dropped by 23.47% to $464.3 million in 2024, then climbed by 0.05% to $464.5 million in 2025, then declined by 1.92% to $455.6 million in 2026.
• Business Quant data shows TWST's Equity Average at $455.6 million in Q1 2026, $464.5 million in Q4 2025, and $475.6 million in Q3 2025.